Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 82
Filtrar
1.
J Dent Res ; 100(6): 599-607, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33356775

RESUMO

As the most common chronic disease in preschool children in the United States, early childhood caries (ECC) has a profound impact on a child's quality of life, represents a tremendous human and economic burden to society, and disproportionately affects those living in poverty. Caries risk assessment (CRA) is a critical component of ECC management, yet the accuracy, consistency, reproducibility, and longitudinal validation of the available risk assessment techniques are lacking. Molecular and microbial biomarkers represent a potential source for accurate and reliable dental caries risk and onset. Next-generation nucleotide-sequencing technology has made it feasible to profile the composition of the oral microbiota. In the present study, 16S ribosomal RNA (rRNA) gene sequencing was applied to saliva samples that were collected at 6-mo intervals for 24 mo from a subset of 56 initially caries-free children from an ongoing cohort of 189 children, aged 1 to 3 y, over the 2-y study period; 36 children developed ECC and 20 remained caries free. Analyses from machine learning models of microbiota composition, across the study period, distinguished between affected and nonaffected groups at the time of their initial study visits with an area under the receiver operating characteristic curve (AUC) of 0.71 and discriminated ECC-converted from healthy controls at the visit immediately preceding ECC diagnosis with an AUC of 0.89, as assessed by nested cross-validation. Rothia mucilaginosa, Streptococcus sp., and Veillonella parvula were selected as important discriminatory features in all models and represent biomarkers of risk for ECC onset. These findings indicate that oral microbiota as profiled by high-throughput 16S rRNA gene sequencing is predictive of ECC onset.


Assuntos
Cárie Dentária , Microbiota , Pré-Escolar , Cárie Dentária/diagnóstico , Cárie Dentária/epidemiologia , Suscetibilidade à Cárie Dentária , Humanos , Microbiota/genética , Micrococcaceae , Qualidade de Vida , RNA Ribossômico 16S/genética , Reprodutibilidade dos Testes , Veillonella
2.
Acta Anaesthesiol Scand ; 61(10): 1305-1313, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28901538

RESUMO

BACKGROUND: The relationship between fatigue-related risk and impaired clinical performance is not entirely clear. Non-technical factors represent an important component of clinical performance and may be sensitive to the effects of fatigue. The hypothesis was that the sum score of overall non-technical performance is degraded by fatigue. METHODS: Nineteen physicians undertook two different simulated air ambulance missions, once when rested, and once when fatigued (randomised crossover design). Trained assessors blinded to participants' fatigue status performed detailed structured assessments based on expected behaviours in four non-technical skills domains: teamwork, situational awareness, task management, and decision making. Participants also provided self-ratings of their performance. The primary endpoint was the sum score of overall non-technical performance. RESULTS: The main finding, the overall non-technical skills performance rating of the clinicians, was better in rested than fatigued states (mean difference with 95% CI, 2.8 [2.2-3.4]). The findings remained consistent across individual non-technical skills domains; also when controlling for an order effect and examining the impact of a number of possible covariates. There was no difference in self-ratings of clinical performance between rested and fatigued states. CONCLUSION: Non-technical performance of critical care air transfer clinicians is degraded when they are fatigued. Fatigued clinicians may fail to recognise the degree to which their performance is compromised. These findings represent risk to clinical care quality and patient safety in the dynamic and isolated environment of air ambulance transfer.


Assuntos
Resgate Aéreo , Competência Clínica , Cuidados Críticos , Fadiga/psicologia , Adulto , Feminino , Humanos , Masculino , Estudos Prospectivos
3.
J Vet Cardiol ; 19(2): 132-143, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28283317

RESUMO

OBJECTIVES: To determine the short-term safety and biologic activity of radiation therapy (RT) for presumptive cardiac hemangiosarcoma in pet dogs. ANIMALS: Six dogs with echocardiographic evidence of a right atrial/auricular mass, and hemorrhagic pericardial effusion, were enrolled in a prospective, single-arm clinical trial. METHODS: A single fraction of 12 Gy was delivered using conformal external beam irradiation. Serum cardiac troponin I and plasma concentrations of vascular endothelial growth factor were quantified before, 4 and 24 h after RT. The frequency of required pericardiocenteses (quantified as the number of pericardiocenteses per week) before RT was compared to that after treatment. Overall survival time was determined. RESULTS: No treatment-related complications were observed. Pericardiocentesis was performed an average of 0.91 times per week before RT, and an average of 0.21 times per week after RT; this difference was statistically significant (p=0.03, as compared using a Wilcoxon signed-rank test of paired data). Pre- and post-treatment plasma vascular endothelial growth factor concentrations were not significantly different at any time point; there was a statistically significant (p=0.04; Friedman's test for non-parametric repeated measures) increase in cardiac troponin concentrations 4 h after irradiation. Median overall survival time was 79 days. CONCLUSIONS: In this population of dogs, RT was delivered without complication, and appears to have reduced the frequency of periacardial tamponade that necessitated pericardiocentesis. Serum cardiac troponin levels are altered after RT. RT alone, or in combination with chemotherapy, may provide clinical benefit to dogs with presumptive diagnoses of cardiac hemangiosarcoma.


Assuntos
Doenças do Cão/radioterapia , Átrios do Coração , Neoplasias Cardíacas/veterinária , Hemangiossarcoma/veterinária , Hemorragia/veterinária , Derrame Pericárdico/veterinária , Animais , Doenças do Cão/diagnóstico por imagem , Cães , Ecocardiografia , Feminino , Neoplasias Cardíacas/complicações , Neoplasias Cardíacas/radioterapia , Hemangiossarcoma/complicações , Hemangiossarcoma/radioterapia , Hemorragia/complicações , Masculino , Derrame Pericárdico/complicações , Projetos Piloto , Complicações Pós-Operatórias/veterinária , Resultado do Tratamento
4.
Am J Surg ; 213(3): 590-595, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28148456

RESUMO

BACKGROUND: Anastomotic leak (AL) increases costs and cancer recurrence. Studies show decreased AL with side-to-side stapled anastomosis (SSA), but none identify risk factors within SSAs. We hypothesized that stapler characteristics and closure technique of the common enterotomy affect AL rates. METHODS: Retrospective review of bowel SSAs was performed. Data included stapler brand, staple line oversewing, and closure method (handsewn, HC; linear stapler [Barcelona technique], BT; transverse stapler, TX). Primary endpoint was AL. Statistical analysis included Fisher's test and logistic regression. RESULTS: 463 patients were identified, 58.5% BT, 21.2% HC, and 20.3% TX. Covidien staplers comprised 74.9%, Ethicon 18.1%. There were no differences between stapler types (Covidien 5.8%, Ethicon 6.0%). However, AL rates varied by common side closure (BT 3.7% vs. TX 10.6%, p = 0.017), remaining significant on multivariate analysis. CONCLUSION: Closure method of the common side impacts AL rates. Barcelona technique has fewer leaks than transverse stapled closure. Further prospective evaluation is recommended.


Assuntos
Anastomose Cirúrgica/métodos , Fístula Anastomótica/etiologia , Grampeamento Cirúrgico/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Diabetes Mellitus/epidemiologia , Desenho de Equipamento , Feminino , Humanos , Intestinos/cirurgia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Duração da Cirurgia , Estudos Retrospectivos , Fatores de Risco , Grampeamento Cirúrgico/instrumentação , Adulto Jovem
6.
Ultrasound Obstet Gynecol ; 45(6): 631-8, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25904437

RESUMO

OBJECTIVE: To determine if prenatal diagnosis improves the chance that a newborn with critical congenital heart disease will survive to undergo planned cardiac surgery. METHODS: A systematic review of the medical literature identified eight studies which met the following criteria: compared outcomes between newborns with prenatal and those with postnatal diagnosis of critical congenital heart disease; compared groups of patients with the same anatomical diagnosis; provided detailed information on cardiac anatomy; included detailed information on preoperative cause of death. A meta-analysis was performed to assess differences in preoperative mortality rates between newborns with prenatal diagnosis and those with postnatal diagnosis. Patients with established risk factors for increased mortality (high risk) and those whose families chose comfort care rather than cardiac surgery were excluded. RESULTS: In patients with comparable anatomy, standard risk, a parental desire to treat and optimal care, newborns with a prenatal diagnosis of critical congenital heart disease were significantly less likely to die prior to planned cardiac surgery than were those with a comparable postnatal diagnosis (pooled odds ratio, 0.26; 95% CI, 0.08-0.84). CONCLUSIONS: For newborns most likely to benefit from treatment for their critical congenital heart disease, because they did not have additional risk factors and their families pursued treatment, prenatal diagnosis reduced the risk of death prior to planned cardiac surgery relative to patients with a comparable postnatal diagnosis. Further study and efforts to improve prenatal diagnosis of congenital heart disease should therefore be considered.


Assuntos
Cardiopatias Congênitas/diagnóstico por imagem , Ultrassonografia Pré-Natal , Feminino , Cardiopatias Congênitas/mortalidade , Cardiopatias Congênitas/cirurgia , Humanos , Recém-Nascido , Gravidez , Resultado da Gravidez , Fatores de Risco
7.
J Vet Intern Med ; 28(4): 1235-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24962737

RESUMO

BACKGROUND: Information regarding cardiac changes in domestic cats with acromegaly is limited. HYPOTHESIS/OBJECTIVES: The objective of this study was to describe the echocardiographic findings in cats with acromegaly. ANIMALS: Eighteen cats diagnosed with acromegaly at Colorado State University between 2008 and 2012. Of these 18 cats, 11 had echocardiography performed. METHODS: A retrospective review of medical records was made to identify cats with acromegaly that also had echocardiography performed. RESULTS: Of the 11 cats identified, 7 had left ventricular concentric hypertrophy, 6 had left atrial enlargement, and 7 had evidence of abnormal diastolic function. All 11 cats had evidence of structural or functional cardiac disease. CONCLUSIONS AND CLINICAL IMPORTANCE: Cardiovascular abnormalities frequently are present in cats with acromegaly, and a complete cardiac evaluation should be considered in these patients.


Assuntos
Acromegalia/veterinária , Doenças do Gato/diagnóstico por imagem , Acromegalia/complicações , Acromegalia/diagnóstico por imagem , Animais , Gatos , Ecocardiografia/veterinária , Feminino , Átrios do Coração/diagnóstico por imagem , Cardiopatias/diagnóstico por imagem , Cardiopatias/etiologia , Cardiopatias/veterinária , Hipertrofia Ventricular Esquerda/diagnóstico por imagem , Hipertrofia Ventricular Esquerda/veterinária , Masculino , Estudos Retrospectivos
8.
Cell Death Differ ; 20(9): 1194-208, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23764775

RESUMO

In patients with Duchenne muscular dystrophy (DMD), the absence of a functional dystrophin protein results in sarcolemmal instability, abnormal calcium signaling, cardiomyopathy, and skeletal muscle degeneration. Using the dystrophin-deficient sapje zebrafish model, we have identified microRNAs (miRNAs) that, in comparison to our previous findings in human DMD muscle biopsies, are uniquely dysregulated in dystrophic muscle across vertebrate species. MiR-199a-5p is dysregulated in dystrophin-deficient zebrafish, mdx(5cv) mice, and human muscle biopsies. MiR-199a-5p mature miRNA sequences are transcribed from stem loop precursor miRNAs that are found within the introns of the dynamin-2 and dynamin-3 loci. The miR-199a-2 stem loop precursor transcript that gives rise to the miR-199a-5p mature transcript was found to be elevated in human dystrophic muscle. The levels of expression of miR-199a-5p are regulated in a serum response factor (SRF)-dependent manner along with myocardin-related transcription factors. Inhibition of SRF-signaling reduces miR-199a-5p transcript levels during myogenic differentiation. Manipulation of miR-199a-5p expression in human primary myoblasts and myotubes resulted in dramatic changes in cellular size, proliferation, and differentiation. MiR-199a-5p targets several myogenic cell proliferation and differentiation regulatory factors within the WNT signaling pathway, including FZD4, JAG1, and WNT2. Overexpression of miR-199a-5p in the muscles of transgenic zebrafish resulted in abnormal myofiber disruption and sarcolemmal membrane detachment, pericardial edema, and lethality. Together, these studies identify miR-199a-5p as a potential regulator of myogenesis through suppression of WNT-signaling factors that act to balance myogenic cell proliferation and differentiation.


Assuntos
Diferenciação Celular/genética , MicroRNAs/biossíntese , MicroRNAs/genética , Distrofia Muscular Animal/genética , Via de Sinalização Wnt/genética , Animais , Proteínas de Ligação ao Cálcio/metabolismo , Linhagem Celular , Proliferação de Células , Dinamina II/genética , Dinamina III/genética , Distrofina/deficiência , Distrofina/genética , Distrofina/metabolismo , Receptores Frizzled/metabolismo , Células HEK293 , Humanos , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Sequências Repetidas Invertidas/genética , Proteína Jagged-1 , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Desenvolvimento Muscular , Fibras Musculares Esqueléticas/metabolismo , Músculo Esquelético , Distrofia Muscular Animal/metabolismo , Mioblastos/metabolismo , Proteínas Nucleares/metabolismo , Proteínas Serrate-Jagged , Fator de Resposta Sérica/metabolismo , Transativadores/metabolismo , Proteína Wnt2/metabolismo , Peixe-Zebra , Proteínas de Peixe-Zebra
9.
J Phys Chem A ; 117(1): 34-41, 2013 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-23210463

RESUMO

We report simulations of the two-dimensional electronic spectroscopy of the Q(y) band of the D1-D2-Cyt b559 photosystem II reaction center at 77 K. We base the simulations on an existing Hamiltonian that was derived by simultaneous fitting to a wide range of linear spectroscopic measurements and described within modified Redfield theory. The model obtains reasonable agreement with most aspects of the two-dimensional spectra, including the overall peak shapes and excited state absorption features. It does not reproduce the rapid equilibration from high energy to low energy excitonic states evident by a strong cross-peak below the diagonal. We explore modifications to the model to incorporate new structural data and improve agreement with the two-dimensional spectra. We find that strengthening the system-bath coupling and lowering the degree of disorder significantly improves agreement with the cross-peak feature, while lessening agreement with the relative diagonal/antidiagonal width of the 2D spectra. We conclude that two-dimensional electronic spectroscopy provides a sensitive test of excitonic models of the photosystem II reaction center and discuss avenues for further refinement of such models.


Assuntos
Simulação por Computador , Modelos Moleculares , Complexo de Proteína do Fotossistema II/química , Análise Espectral/métodos , Transferência de Energia , Conformação Proteica
10.
Eur Respir J ; 33(1): 142-7, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18829671

RESUMO

Although the presence of neutropenia may predispose cancer patients to develop community-acquired pneumonia, the role of neutropenia on their outcomes has not been investigated. The purpose of the present study was to compare clinical outcomes of cancer community-acquired pneumonia patients with and without neutropenia. Patients with cancer, identified in the Community-Acquired Pneumonia Organization database, were divided into two groups according to the type of cancer and the presence of neutropenia: patients with solid cancer without neutropenia versus those with functional or absolute neutropenia. Among the 3,106 community-acquired pneumonia patients enrolled, 135 had cancer without neutropenia and 75 had cancer with neutropenia. No significant difference was found between patients with and without neutropenia regarding mean time to clinical stability (5.4+/-2.7 versus 4.9+/-2.7 days, respectively), mean length of hospital stay (9.2+/-7.7 versus 9.9+/-9.6 days) and in-hospital mortality (18 versus 15%, respectively). Using a multiple logistic regression model, neutropenia was not associated with mortality in cancer patients when adjusting for significant covariates (odds ratio 1.30). Lack of neutropenia, during the initial evaluation of a cancer community-acquired pneumonia patient, should not be considered an indicator of better clinical outcome.


Assuntos
Neoplasias/complicações , Neutropenia/complicações , Pneumonia/complicações , Pneumonia/mortalidade , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Infecções Comunitárias Adquiridas/complicações , Infecções Comunitárias Adquiridas/mortalidade , Infecções Comunitárias Adquiridas/terapia , Bases de Dados Factuais , Feminino , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Neoplasias/mortalidade , Neoplasias/terapia , Neutropenia/mortalidade , Neutropenia/terapia , Pneumonia/terapia , Estudos Retrospectivos , Fatores de Risco , Taxa de Sobrevida , Resultado do Tratamento
12.
Surg Endosc ; 22(1): 208-13, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17721807

RESUMO

BACKGROUND: Intraoperative fluorocholangiography (IOC) has been the standard method for bile duct imaging during cholecystectomy. Laparoscopic ultrasound (LUS) has been evaluated as a possible alternative, but has been used less frequently. The authors examined the evolving use of these two methods to assess the relative utility of LUS as the primary method for routine bile duct imaging during laparoscopic cholecystectomy (LC). METHODS: This study analyzed a prospective database containing 423 consecutive cholecystectomies performed by one attending surgeon in an academic medical center between 1995 and 2005. RESULTS: Intraoperative bile duct imaging was performed in 371 (94%) of 396 LCs performed for cholelithiasis. As recorded, IOC was performed in 239 cases, LUS in 236 cases, and both in 104 cases. Choledocholithiasis was present in 50 patients (13%). Common bile duct stones (CBDS) were identified by LUS in 3% of the patients without preoperative indicators of CBDS, and in 10% of the patients with one or more indicators. As shown by the findings, LUS had a positive predictive value of 100%, a negative predictive value of 99.6%, a sensitivity of 92.3%, and a specificity of 100% for detecting CBDS. Also, LUS identified clinically significant bile duct anatomy in 6% of the patients. In 1995, LUS was used for 20% of cases, whereas by 2005, it was used for 97% of cases. Conversely, the use of IOC decreased from 93% to 23%. CONCLUSIONS: With moderate experience, LUS can become the primary routine imaging method for evaluating the bile duct during LC. It is as reliable as IOC for detecting choledocholithiasis. In addition, LUS can locate the common bile duct during difficult dissections. On the basis of this experience, LUS is used currently in nearly all LCs and is the sole method for bile duct imaging in 75% of these cases. IOC is used as an adjunct to LUS when LUS imaging is inadequate, when stronger clinical indicators of choledocholithiasis are present, or when biliary anatomy remains uncertain.


Assuntos
Ductos Biliares/diagnóstico por imagem , Colangiopancreatografia Retrógrada Endoscópica/métodos , Colecistectomia Laparoscópica/métodos , Endossonografia/métodos , Colecistectomia Laparoscópica/efeitos adversos , Feminino , Seguimentos , Humanos , Masculino , Monitorização Intraoperatória/métodos , Complicações Pós-Operatórias/prevenção & controle , Sistema de Registros , Estudos Retrospectivos , Medição de Risco , Sensibilidade e Especificidade , Resultado do Tratamento
15.
Chirurg ; 73(7): 716-20, 2002 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-12242982

RESUMO

BACKGROUND: The inhibition of tumorangiogenesis may be of importance in the additive treatment of various cancers. Leflunomide, a drug which has been approved in Germany for the therapy of rheumatoid arthritis, inhibits the activity of several growth factors in vitro. The aim of this study was to investigate the effects of the drug on tumor angiogenesis in a nude mouse model. MATERIALS AND METHODS: A total of 40 nude mice were injected with human colon carcinoma cells. Following randomization in 4 groups, therapy started on day five. Group 1 was treated daily with orally administered Leflunomide (35 mg/kg) dissolved in 1.5% Carboxymethylcellulose (CMC). Group 2 served as a control group and received 1 ml CMC orally per day. The animals of group 3 were treated daily with 35 mg Leflunomide/kg KG and 500 mg Uridine/kg dissolved in 1 ml Nacl 0.9% intraperitoneally. The 4th group again served as a control group and received only 500 mg Uridine/kg intraperitoneally each day. The main outcome criterion was the angiogenesis score (AS). In addition, the tumor volume and tumor weight were also assessed. The AS was determined by immunohistochemistry using an antibody against factor VIII related antigen. RESULTS: All animals tolerated the procedure well. In the Leflunomide and the Leflunomide/Uridine group the angiogenesis score (p < 0.01), the tumor volume (p < 0.01) and the tumor weight (p < 0.01) were lower compared to the respective control groups. CONCLUSION: The administration of Leflunomide leads to a significant reduction of tumor weight and tumor volume following subcutaneous injection of human colon carcinoma cells in a nude mouse model. This could be due to the reduction of tumor angiogenesis. Following further experimental and clinical studies, Leflunomide may come to play a role in the additive treatment of colonic carcinoma.


Assuntos
Divisão Celular/efeitos dos fármacos , Neoplasias do Colo/irrigação sanguínea , Isoxazóis/farmacologia , Neovascularização Patológica/patologia , Administração Oral , Animais , Capilares/efeitos dos fármacos , Capilares/patologia , Neoplasias do Colo/patologia , Células HT29/efeitos dos fármacos , Células HT29/patologia , Humanos , Injeções Intraperitoneais , Leflunomida , Camundongos , Camundongos Nus , Transplante de Neoplasias , Distribuição Aleatória , Uridina/farmacologia
16.
IEEE Trans Biomed Eng ; 48(6): 695-705, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11396599

RESUMO

In Barrett's esophagus, the precursor to esophageal adenocarcinoma, the squamocolumnar junction (SCJ) between the normal esophagus and the stomach like mucosa is proximally displaced. Currently it can be detected only by an expensive upper GI endoscopic procedure. We have developed a minimally invasive and easy to operate colorimetric instrument for the low-cost detection of Barrett's esophagus. The instrument is based on a flexible, narrow diameter, fiber-optic probe that performs a colorimetric scan of the esophageal lumen. The instrument was clinically evaluated in 50 subjects. The instrument could identify both symmetric and asymmetric SCJ's. The SCJ locations determined by the colorimetric instrument correlated strongly (R2 = 0.89) with those determined by endoscopy. The instrument identified the SCJ locations accurately (Mean of difference +/- SEM: 0.97 +/- 1.72 cm) and reproducibly (Mean of absolute difference +/- SEM: 1.33 +/- 1.40 cm). The instrument has a 90% sensitivity of identifying patients with Barrett's esophagus, based on the clinical algorithm that if the SCJ is located at a distance less than 37 cm from the teeth, then the subject has Barrett's esophagus, otherwise the subject does not have Barrett's esophagus. In conclusion, the colorimetric instrument has the potential of being a cost-effective way of determining patients likely to have Barrett's esophagus in the population.


Assuntos
Esôfago de Barrett/diagnóstico , Colorimetria/instrumentação , Tecnologia de Fibra Óptica , Adenocarcinoma/diagnóstico , Idoso , Algoritmos , Diagnóstico Diferencial , Desenho de Equipamento , Neoplasias Esofágicas/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fibras Ópticas
18.
Am Surg ; 66(4): 401-5; discussion 405-6, 2000 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10776879

RESUMO

A retrospective study of surgically resectable esophageal cancers was undertaken to determine the relationship between angiogenesis score and growth factor expression with tumor size, histology, degree of differentiation, depth of invasion, nodal disease, and the presence of Barrett's esophagus. The office and hospital charts of 27 patients who had esophageal resection for carcinoma between 1990 and 1995 at Rush-Presbyterian-St. Luke's Medical Center were reviewed. Data collection included patient demographics, survival, tumor size, histology, differentiation, depth of invasion, nodal metastases, and the presence of Barrett's esophagus. The pathology specimens were immunostained for von Willebrand factor (factor VIII-related antigen). Immunostaining was also performed for vascular endothelial growth factor and transforming growth factor alpha. Twenty normal esophageal specimens served as controls. Angiogenesis score was determined by counting vessels under conventional light microscopy at x200 magnification, and growth factor expression was graded on a scale of 1 to 4. Cancers had higher angiogenesis and growth factor expression than controls (P = 0.01). Patient age, tumor size, histology, differentiation, depth of invasion, and Barrett's esophagus did not correlate with angiogenesis score or tumor growth factor expression. Lymph node status did correlate with both angiogenesis score and growth factor expression (P < or = 0.02). We conclude that high angiogenesis score and growth factor expression correlate with the presence of lymph node metastases. This may help select patients for preoperative radiation and chemotherapy or determine the extent of surgery performed for esophageal carcinoma.


Assuntos
Biomarcadores Tumorais/metabolismo , Carcinoma/metabolismo , Fatores de Crescimento Endotelial/metabolismo , Neoplasias Esofágicas/metabolismo , Linfocinas/metabolismo , Neovascularização Patológica/metabolismo , Fator de Crescimento Transformador alfa/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Esôfago de Barrett/etiologia , Esôfago de Barrett/metabolismo , Carcinoma/complicações , Carcinoma/patologia , Carcinoma/cirurgia , Neoplasias Esofágicas/complicações , Neoplasias Esofágicas/patologia , Neoplasias Esofágicas/cirurgia , Esofagectomia , Feminino , Humanos , Metástase Linfática/fisiopatologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Estatísticas não Paramétricas , Análise de Sobrevida , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular , Fator de von Willebrand/metabolismo
19.
Biochem Pharmacol ; 58(9): 1405-13, 1999 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-10513984

RESUMO

Leflunomide, a novel immunomodulatory drug, has two biochemical activities: inhibition of tyrosine phosphorylation and inhibition of pyrimidine nucleotide synthesis. In the present study, we first showed that A77 1726 [N-(4-trifluoromethylphenyl-2-cyano-3-hydroxycrotoamide)], the active metabolite of leflunomide, was more effective at inhibiting the tyrosine kinase activity of platelet-derived growth factor (PDGF) receptor than that of epidermal growth factor (EGF) receptor, and had no effect on the tyrosine kinase activity of the fibroblast growth factor receptor. In the presence of exogenous uridine, A77 1726 was more effective at inhibiting the PDGF-stimulated proliferation of PDGF receptor-overexpressing C6 glioma than the EGF-stimulated proliferation of EGF receptor-overexpressing A431 cells. In vivo studies demonstrated that leflunomide treatment strongly inhibited the growth of the C6 glioma but had only a modest effect on the growth of the A431 tumor. Uridine co-administered with leflunomide did not reverse the antitumor activity of leflunomide on C6 and A431 tumors significantly. Quantitation of nucleotide levels in the tumor tissue revealed that leflunomide treatment significantly reduced pyrimidine nucleotide levels in the fast-growing C6 glioma but had no effect on the relatively slow-growing A431 tumor. Whereas uridine co-administration normalized pyrimidine nucleotide levels, it had minimal effects on the antitumor activity of leflunomide in both tumor models. Immunohistochemical analysis revealed that leflunomide treatment significantly reduced the number of proliferating cell nuclear antigen-positive cells in C6 glioma, and that uridine only partially reversed this inhibition. These results collectively suggest that the in vivo antitumor effect of leflunomide is largely independent of its inhibitory effect on pyrimidine nucleotide synthesis. The possibility that leflunomide exerts its antitumor activity by inhibition of tyrosine phosphorylation or by a yet unidentified mode of action is discussed.


Assuntos
Adjuvantes Imunológicos/farmacologia , Antineoplásicos/farmacologia , Isoxazóis/farmacologia , Células 3T3 , Compostos de Anilina/farmacologia , Animais , Antineoplásicos/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/metabolismo , Divisão Celular/efeitos dos fármacos , Crotonatos , Ensaios de Seleção de Medicamentos Antitumorais , Receptores ErbB/biossíntese , Receptores ErbB/metabolismo , Feminino , Glioma/tratamento farmacológico , Glioma/metabolismo , Hidroxibutiratos/farmacologia , Imunossupressores/farmacologia , Isoxazóis/uso terapêutico , Leflunomida , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Transplante de Neoplasias , Nitrilas , Fosforilação/efeitos dos fármacos , Nucleotídeos de Pirimidina/biossíntese , Receptores de Fatores de Crescimento/metabolismo , Receptores do Fator de Crescimento Derivado de Plaquetas/biossíntese , Receptores do Fator de Crescimento Derivado de Plaquetas/metabolismo , Toluidinas , Células Tumorais Cultivadas , Tirosina/metabolismo
20.
Chirurg ; 70(6): 700-4, 1999 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-10427458

RESUMO

UNLABELLED: Hemorrhagic proctitis is a rare, but severe complication of radiation therapy in the treatment of several pelvic malignancies. Administration of topical steroids, anti-inflammatory agents or laser therapy and rectal instillation of 4% formalin have been described as a method of treating this complication. A dog model was established to study the safest volume and duration of administration of formalin, the histological changes in the rectal mucosa, and rectal compliance following this treatment. METHOD: Twenty-one mongrel dogs were assigned randomly to seven groups. Three dogs received a rectal formalin bolus of 400 ml for 1 h; in the other six groups formalin was instilled in 30 ml aliquots to a total volume of 400 ml. Serum levels of formalin were obtained at designated time intervals, rectal compliance was evaluated pre- and post-formalin instillation, and rectal mucosa was analyzed for blood-vessel density and mucosal injury at different time points. RESULTS: Serum formalin in the bolus group reached toxic levels, while sequential instillation caused no serum toxicity in any dog. Rectal compliance and mucosal thickness were not affected by formalin, but there was a decrease in the angiogenesis score, and mild proctitis was seen in the acute and 1-week group.


Assuntos
Formaldeído/administração & dosagem , Hemorragia Gastrointestinal/tratamento farmacológico , Proctite/tratamento farmacológico , Animais , Complacência (Medida de Distensibilidade) , Cães , Mucosa Gástrica/efeitos dos fármacos , Mucosa Gástrica/patologia , Hemorragia Gastrointestinal/patologia , Humanos , Instilação de Medicamentos , Neoplasias Pélvicas/radioterapia , Proctite/patologia , Lesões por Radiação/tratamento farmacológico , Lesões por Radiação/patologia , Reto/patologia , Reto/efeitos da radiação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...